These results are in line with previous reports of nuclear ABCG2 shuttling in lung cancer resulting in reduced cell migration and increased differentiation [65, 66], with consequently a decreased ABC transporter efflux activity at the cell membrane expected to reduce drug resistance [67]. The gene discussed is ABCG2; the disease is lung cancer.